Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
25. November 2024 16:01 ET
|
Barinthus Biotherapeutics
OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D.,...
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
06. November 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
bioLytical Laboratories Inc. Announces Health Canada Authorization of its rapid INSTI® HCV Antibody Test for Professional Use in Canada
04. November 2024 12:00 ET
|
bioLytical Laboratories Inc.
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Canadian market
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
31. Oktober 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
28. Oktober 2024 08:05 ET
|
BlueWillow Biologics
ANN ARBOR, Mich., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc., a clinical-stage biotech company pioneering the future of intranasal vaccines, today announced that the company will...
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
01. Oktober 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
08. August 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12. Juni 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
06. Juni 2024 11:15 ET
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
Dyadic to Attend Industry Events in June
30. Mai 2024 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...